Concepedia

Silke Appel‐Dingemanse

SA

Statistics

Publications

22

Citations

990

H-Index

15

Active since

1999

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Novartis (France)

Tris Pharma (United States)

Novartis (United Kingdom)

Silke Appel‐Dingemanse is an author at Novartis (Switzerland) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

1999–2009

22

Publications

22

Tegaserod, a 5‐HT <sub>4</sub> receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

Lukas Degen, Daniel Matzinger, Michael Merz et al. · Alimentary Pharmacology & Therapeutics · 2001 · 210 citations · Full text

, , +15

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients

Gilbert Lefèvre, G Sędek, S. S. Jhee et al. · Clinical Pharmacology & Therapeutics · 2007 · 130 citations · Full text

, , +17

A PHASE I STUDY OF A 4-WEEK COURSE OF SDZ-RAD (RAD) IN QUIESCENT CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS1,2

Barry D. Kahan, Robert Wong, Stephen H. Katz et al. · Transplantation · 1999 · 109 citations

, , +15

Rivastigmine exposure provided by a transdermal patch versus capsules

François Mercier, Gilbert Lefèvre, Hsun‐Lun Aaron Huang et al. · Current Medical Research and Opinion · 2007 · 78 citations

, , +17

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

Joel Morganroth, Peter C. Rüegg, Cornelia Dunger‐Baldauf et al. · The American Journal of Gastroenterology · 2002 · 70 citations

, , +17

1–5 of 22